Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant progress with two first-in-class therapies: IBSRELA (tenapanor) for irritable ...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street ...